Treatment emergent adverse events occurring in 5 or more patients and relationships* to study drug treatment
| Adverse event | Treatment-Emergent adverse events N = 22 Number of patients (%) | |||
|---|---|---|---|---|
| All | AGS-003 related** | Sunitinib related | Combination related | |
| Any | 22 (100) | 17 (77) | 22 (100) | 12 (55) |
| Diarrhea | 13 (59) | 3 (14) | 11 (50) | 3 (14) |
| Fatigue | 13 (59) | 3 (14) | 12 (55) | 2 (9) |
| Nausea | 12 (55) | 2 (9) | 11 (50) | 2 (9) |
| Rash | 10 (46) | 4 (18) | 9 (41) | 5 (23) |
| Decreased weight | 9 (41) | 1 (5) | 5 (23) | 1 (5) |
| Headache | 8 (36) | 2 (9) | 4 (18) | 2 (9) |
| Injection-site erythema | 8 (36) | 7 (32) | 0 | 0 |
| Peripheral edema | 8 (36) | 0 | 4 (18) | 0 |
| Dyspnea | 7 (32) | 0 | 1 (5) | 0 |
| Vomiting | 7 (32) | 0 | 7 (32) | 0 |
| Anorexia | 6 (27) | 0 | 5 (23) | 1 (5) |
| Hypertension | 6 (27) | 1 (5) | 6 (27) | 1 (5) |
| Hypothyroidism | 6 (27) | 0 | 5 (23) | 1 (5) |
| Hand-foot syndrome | 6 (27) | 0 | 6 (27) | 0 |
| Constipation | 5 (23) | 0 | 2 (9) | 0 |
| Dehydration | 5 (23) | 0 | 2 (9) | 0 |
| Dysgeusia | 5 (23) | 1 (5) | 5 (23) | 1 (5) |
| Injection-site induration | 5 (23) | 5 (23) | 0 | 1 (5) |
*Events described as possible, probably or definitely related to study drug.
**All AGS-003 related events were Grade 1 or 2 in severity.